Related Experiment Video
Updated: Jan 24, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Safety of Abiraterone Acetate Administration in Elderly Patients Receiving Peritoneal Dialysis with
Ryoji Kimata1, Yuji Tomita1, Yukihiro Kondo2
1Department of Urology, Nippon Medical School Musashi Kosugi Hospital.
Abstract:
We report two elderly patients receiving peritoneal dialysis with castration-resistant prostate cancer (CRPC). Herein, we show that the patients were safely treated using abiraterone acetate (750 mg/day orally once daily) and prednisolone (5 mg/day orally once daily). Although the prostate-specific antigen (PSA) level increased in both cases, there was no manifestation of disease progression (clinical and radiographic) for 22 months in case 1 and 8 months in case 2. In case 2, the only adverse event was hypokalemia, which was treated using potassium preparations.
Related Concept Videos
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis I: Introduction and Procedure
Peritoneal Dialysis III: Nursing Management
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Treatment Resistant Cancers
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...

